Duchenne氏肌肉失養症治療市場按治療方法、治療類型、最終用戶和地區分類

Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, By End User, and By Geography

出版日期: 2025年04月23日 | 出版商:

Coherent Market Insights | 英文 169 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

Duchenne氏肌肉失養症治療市場規模預計在 2025 年為 89.887 億美元，預計到 2032 年將達到 13881.81 億美元，2025 年至 2032 年的複合年成長率為 47.85%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	89.887億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年複合年成長率：	47.85%	2032年價值預測	138,818,100,000美元

圖：2025年Duchenne氏肌肉失養症治療市場佔有率（%），依地區分類

Duchenne氏肌肉失養症(DMD) 是一種肌肉萎縮症。它是一種遺傳性疾病，其特徵是由於一種名為抗肌進行性Dystrophin的蛋白質（該蛋白質負責維持肌肉細胞完整）的變化而Duchenne氏肌肉失養症主要影響男性，但在極少數情況下，女性也可能患上這種疾病。

市場動態：

Duchenne氏肌肉失養症(DMD) 盛行率不斷上升、對新型藥物和治療方法的需求不斷增加、研發 (R&D)活性化以及公眾對 DMD 和現有藥物和治療方法的認知不斷提高是預計將促進全球Duchenne氏肌肉失養症治療市場成長的主要因素。

例如，2022年5月，Stealth BioTherapeutics Corp.宣布，美國食品藥物管理局（FDA）授予elamipretide孤兒藥資格，用於治療Duchenne氏肌肉失養症（DMD）。

此外，輝瑞公司計劃於 2022 年 4 月在美國開設第一個試驗點，進行 3 期試驗，評估 fordaistrogene movaparvovec（一種臨床實驗微型Dystrophin萎縮蛋白基因療法）對Duchenne氏肌肉失養症(DMD)門診病人的效果。

本研究的主要特點

本報告對Duchenne氏肌肉失養症治療市場進行了詳細分析，並提供了預測期 2025-2032 的市場規模和複合年成長率（以 2024 年為基準年）。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
全球Duchenne氏肌肉失養症治療市場的主要企業是根據公司亮點、產品系列、主要亮點、績效和策略等參數進行分析的。
人們相信，本報告的見解可以幫助負責人和公司經營團隊就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球Duchenne氏肌肉失養症治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
透過用於分析全球Duchenne氏肌肉失養症治療市場的各種策略矩陣，可以幫助相關人員做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 8,988.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	47.85%	2032 Value Projection:	USD 138,818.1 Mn

Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy. It is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin, which helps keep muscle cells intact. DMD affects the muscles, leading to muscle wasting that gets worse over time. Duchenne muscular dystrophy occurs primarily in males, though in rare cases may affect females.

Market Dynamics:

Increase in prevalence of Duchenne muscular dystrophy (DMD), increase in demand for novel drugs or therapies, rise in research and development (R&D), and increase in awareness among people about DMD and available drugs/therapies are major factors expected to augment growth of the global Duchenne muscular dystrophy treatment market.

For instance, In May 2022, Stealth BioTherapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Elamipretide for the treatment of Duchenne Muscular Dystrophy (DMD).

Moreover, in April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy (DMD).

Key features of the study:

This report provides in-depth analysis of the Duchenne muscular dystrophy treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Duchenne muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., BioMarin, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Fibrogen Inc., NS Pharma Inc., Nobelpharma Co. Ltd., Bristol-Myers Squibb, and Eli Lilly and Company.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global Duchenne muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Duchenne muscular dystrophy treatment market.

Detailed Segmentation:

Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type
- Molecular-based Therapies
- Steroid Therapy
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Other Therapeutic Approaches and Treatment Types
Global Duchenne Muscular Dystrophy Treatment Market, By End User
- Hospitals/Clinics
- Ambulatory Centers
- Other End Users
Global Duchenne Muscular Dystrophy Treatment Market, By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- Pfizer Inc.
- Fibrogen Inc.
- BioMarin
- Sarepta Therapeutics
- Santhera Pharmaceuticals
- PTC Therapeutics
- NS Pharma Inc.
- Nobelpharma Co. Ltd.
- Bristol-Myers Squibb
- Eli Lilly and Company

Market Dynamics
- Rise in prevalence of Duchenne muscular dystrophy
- Lack of standardization and stringent rules/regulations
- Increase in demand for novel drugs or therapies
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Duchenne Muscular Dystrophy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Molecular-based Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Steroid Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Other Therapeutic Approaches and Treatment Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Duchenne Muscular Dystrophy Treatment Market, By End User, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals/Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Other End Users
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Duchenne Muscular Dystrophy Treatment Market, By Geography, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fibrogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioMarin
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Santhera Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
NS Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Nobelpharma Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views